文献速递免疫规划卫生政策与健康促进

BBIBP-CorV初种后异源Ad26.COV2.S加强针对SARS-CoV-2感染的1年随访:1/2期开放标签试验

Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
PubMed 文献 · Vaccine · 2024-05-13

该1/2期开放标签试验在健康泰国成人中评估BBIBP-CorV初种后异源Ad26.COV2.S加强针的1年免疫应答。加强针后1年仍可检测到加强针特异性免疫应答,且混合免疫者应答更高。≥60岁者持久应答趋势较低。

要点

  • BBIBP-CorV初种后异源Ad26.COV2.S加强针诱导的加强针特异性免疫应答可持续至1年。
  • 混合免疫参与者加强针后1年的免疫应答高于仅加强针者。
  • ≥60岁者持久免疫应答趋势较低。

核心结论

  • BBIBP-CorV初种后异源Ad26.COV2.S加强针诱导的加强针特异性免疫应答可检测至1年,混合免疫参与者应答更高。

研究设计与样本

  • 开放标签1/2期研究,纳入≥18岁健康泰国成人,初种BBIBP-CorV后90-240天(A1组;n=361)或45-75天(A2组;n=104)入组,均接种Ad26.COV2.S加强针。
  • 在基线血清阴性人群(加强前抗N<1.4 U/mL;n=241)中评估免疫应答,包括加强针效应亚组和混合免疫亚组。

主要发现

  • A1组加强针效应亚组第336天抗S GMC较基线高131倍;第168天针对祖先SARS-CoV-2的中和应答较基线高5倍;第84天针对Omicron BA.2高4倍。
  • 18-59岁者IFN-γ在第168天和第336天仍较基线高约4倍;A2组加强针特异性应答趋势较低。
  • 混合免疫亚组第336天A1组抗S GMC较基线高517倍;针对祖先SARS-CoV-2和Omicron BA.2的中和应答分别高28倍和31倍;18-59岁者第336天IFN-γ高约14倍。
  • ≥60岁者持久免疫应答趋势较低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inactivated whole-virus vaccination elicits immune responses to both SARS-CoV-2 nucleocapsid (N) and spike (S) proteins, like natural infections. A heterologous Ad26.COV2.S booster given at two different intervals after primary BBIBP-CorV vaccination was safe and immunogenic at days 28 and 84, with higher immune responses observed after the longer pre-boost interval. We describe booster-specific and hybrid immune responses over 1 year. METHODS: This open-label phase 1/2 study was conducted in healthy Thai adults aged ≥ 18 years who had completed primary BBIBP-CorV primary vaccination between 90-240 (Arm A1; n = 361) or 45-75 days (Arm A2; n = 104) before enrolment. All received an Ad26.COV2.S booster. We measured anti-S and anti-N IgG antibodies by Elecsys®, neutralizing antibodies by SARS-CoV-2 pseudovirus neutralization assay, and T-cell responses by quantitative interferon (IFN)-γ release assay. Immune responses were evaluated in the baseline-seronegative population (pre-booster anti-N < 1.4 U/mL; n = 241) that included the booster-effect subgroup (anti-N < 1.4 U/mL at each visit) and the hybrid-immunity subgroup (anti-N ≥ 1.4 U/mL and/or SARS-CoV-2 infection, irrespective of receiving non-study COVID-19 boosters). RESULTS: In Arm A1 of the booster-effect subgroup, anti-S GMCs were 131-fold higher than baseline at day 336; neutralizing responses against ancestral SARS-CoV-2 were 5-fold higher than baseline at day 168; 4-fold against Omicron BA.2 at day 84. IFN-γ remained approximately 4-fold higher than baseline at days 168 and 336 in 18-59-year-olds. Booster-specific responses trended lower in Arm A2. In the hybrid-immunity subgroup at day 336, anti-S GMCs in A1 were 517-fold higher than baseline; neutralizing responses against ancestral SARS-CoV-2 and Omicron BA.2 were 28- and 31-fold higher, respectively, and IFN-γ was approximately 14-fold higher in 18-59-year-olds at day 336. Durable immune responses trended lower in ≥ 60-year-olds. CONCLUSION: A heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination induced booster-specific immune responses detectable up to 1 year that were higher in participants with hybrid immunity. CLINICAL TRIALS REGISTRATION: NCT05109559.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Muangnoicharoen S, Wiangcharoen R, Lawpoolsri S, et al. Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial. Vaccine. 2024. PMID: 38744598. doi:10.1016/j.vaccine.2024.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。